Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 14/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15719188 | 1.00 | P2RX3 (0.51) | P2RX3MCL1UCHL1USP30NR1H2 | |
| SCHEMBL948760 | 1.00 | P2RX3 (0.51) | P2RX3MCL1UCHL1USP30NR1H2 | |
| SCHEMBL18103660 | 1.00 | P2RX3 (0.51) | P2RX3MCL1UCHL1USP30NR1H2 | |
| SCHEMBL27112502 | 1.00 | P2RX3 (0.51) | P2RX3MCL1UCHL1USP30NR1H2 | |
| SCHEMBL948762 | 1.00 | P2RX3 (0.51) | P2RX3MCL1UCHL1USP30NR1H2 | |
| SCHEMBL3544314 | 0.93 | MCL1 (0.59) | P2RX3MCL1UCHL1 | |
| SCHEMBL7722217 | 0.90 | MCL1 (0.50) | P2RX3MCL1UCHL1NR1H2NR1H3 | |
| SCHEMBL25365111 | 0.89 | P2RX3 (0.53) | P2RX3MCL1NR1H2NR1H3 | |
| SCHEMBL6846802 | 0.89 | P2RX3 (0.53) | P2RX3MCL1UCHL1NR1H2NR1H3 | |
| SCHEMBL6846804 | 0.89 | P2RX3 (0.53) | P2RX3MCL1UCHL1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253101-A1 | PYRIDAZINONE COMPOUND AS PARP7 INHIBITOR | 上海优理惠生医药有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3712162-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-9969770-B2 | Proline compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20170015706-A1 | PROLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-9458193-B1 | Proline compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-6770741-B1 | USEFUL IN TREATING CONDITIONS AND DISEASES OF A MAMMAL AND HUMAN IN WHICH AN EXCESS OF BRADYKININ OR RELATED KININS ARE PRODUCED OR INJECTED SUCH AS BY INSECT BITES | SCIOS INC. | 2004-08-03 | — | — | US | disclosed |
| EP-0618810-B1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC (US) | 2001-07-04 | — | — | EP | disclosed |
| US-5385889-A | Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist | SCIOS NOVA INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0618810-A4 | BRADYKININ ANTAGONIST PEPTIDES. | SCIOS NOVA INC (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0618810-A1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | P2RX3 3591/4885MCL1 133/4885UCHL1 1397/4885 |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | BIRC7, BIRC5, BIRC2 | P2RX3 4201/4885MCL1 16/4885UCHL1 1053/4885 |
| US-20170015706-A1 | PROLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, CTSB, RNPEP | P2RX3 4517/4885MCL1 2252/4885UCHL1 3054/4885 |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | BIRC7, BIRC5, BIRC2 | P2RX3 4201/4885MCL1 16/4885UCHL1 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.